PMID- 9315335 OWN - NLM STAT- MEDLINE DCOM- 19971230 LR - 20190905 IS - 8756-3282 (Print) IS - 1873-2763 (Linking) VI - 21 IP - 4 DP - 1997 Oct TI - Monocyte chemoattractant protein-1 induces monocyte recruitment that is associated with an increase in numbers of osteoblasts. PG - 321-7 AB - Monocyte chemoattractant protein-1 (MCP-1) is a member of the chemokine family of cytokines. The principal function of MCP-1 is thought to be the stimulation of monocyte recruitment. Monocyte products are potential regulators of bone cell activity. Growth factors produced by monocytes may stimulate bone formation, while cytokines such as IL-1 and IL-6 can induce bone resorption. To determine whether MCP-1 enhances recruitment of monocytes during bone healing, studies were carried out in which MCP-1 was applied to osseous sites in vivo. Changes in monocyte number were determined by immunohistochemistry using the antibody ED-1 specific for peripheral monocytic cells. The effect of MCP-1 on osteoblast number was determined by counting the number of alkaline phosphatase positive cells in close proximity to bone. For comparison, osteoblast number was also determined following stimulation with platelet-derived growth factor (PDGF)-BB plus IGF-1 in vivo. Results indicate that MCP-1 stimulated a large increase in monocyte recruitment compared to vehicle alone. An increase in monocytes induced by MCP-1 was associated with an increase in the number of osteoblasts lining the bone surface, although not to the same magnitude as a positive control, PDGF-BB, and IGF-1. These results indicate that MCP-1 induces the recruitment of monocytes to bone and suggest that the recruitment is associated with an increase in osteoblast number. This is likely to occur via indirect mechanisms, because MCP-1 did not directly enhance DNA synthesis in osteoblastic cells in vitro. Thus, activated mononuclear phagocytes may play an important role in osseous wound healing by stimulating proliferation of osteoblastic cells, presumably through the elaboration of growth factors. FAU - Posner, L J AU - Posner LJ AD - Division of Oral Biology, Boston University School of Dental Medicine, MA, USA. FAU - Miligkos, T AU - Miligkos T FAU - Gilles, J A AU - Gilles JA FAU - Carnes, D L AU - Carnes DL FAU - Taddeo, D R AU - Taddeo DR FAU - Graves, D T AU - Graves DT LA - eng GR - DE07559/DE/NIDCR NIH HHS/United States GR - DE11254/DE/NIDCR NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Bone JT - Bone JID - 8504048 RN - 0 (Anticonvulsants) RN - 0 (Chemokine CCL2) RN - 0 (Platelet-Derived Growth Factor) RN - 0 (Proto-Oncogene Proteins c-sis) RN - 1B56C968OA (Becaplermin) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 9013-72-3 (Hemocyanins) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Alkaline Phosphatase MH - Animals MH - Anticonvulsants/pharmacology MH - Becaplermin MH - Cell Count/drug effects MH - Chemokine CCL2/*pharmacology MH - Hemocyanins MH - Immunohistochemistry MH - Insulin-Like Growth Factor I/pharmacology MH - Male MH - Monocytes/*drug effects/pathology MH - Osteitis/chemically induced/pathology MH - Osteoblasts/*drug effects/pathology MH - Platelet-Derived Growth Factor/pharmacology MH - Proto-Oncogene Proteins c-sis MH - Rats MH - Rats, Sprague-Dawley EDAT- 1997/10/07 00:00 MHDA- 1997/10/07 00:01 CRDT- 1997/10/07 00:00 PHST- 1997/10/07 00:00 [pubmed] PHST- 1997/10/07 00:01 [medline] PHST- 1997/10/07 00:00 [entrez] AID - S8756328297001543 [pii] AID - 10.1016/s8756-3282(97)00154-3 [doi] PST - ppublish SO - Bone. 1997 Oct;21(4):321-7. doi: 10.1016/s8756-3282(97)00154-3.